

RI LANKA 2024

WEEKLY EPIDEMIOLOGICAL REPORT A publication of the Epidemiology Unit

Ministry of Health231, de Saram Place, Colombo 01000, Sri LankaTele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lkEpidemiologist: +94 11 2681548, E mail: chepid@sltnet.lkWeb: http://www.epid.gov.lk

Vol. 51 No. 14

30th - 05th Apr 2024

Epidemiology and Prevention of Typhoid Fever: Disease Dynamics and Vaccination

Epidemiology

Typhoid fever, caused by the bacterium Salmonella Typhi, remains a significant public health concern in low and middle-income countries, particularly in South/Southeast Asia, sub-Saharan Africa, and some island nations of Oceania. Though global estimates suggest a reduction in cases since 2000, the burden remains substantial, with millions of cases and thousands of deaths annually. Undiagnosed cases are common, especially in some regions, highlighting challenges in detection and surveillance. Despite largely being an endemic disease, typhoid fever retains epidemic potential.

Transmission occurs primarily through the fecal -oral route, facilitated by inadequate sanitation and hygiene practices, with both short-cycle (local contamination) and long-cycle (environmental contamination) patterns observed. Factors contributing to transmission include poor access to safe water and sanitation, population density, socioeconomic status, and inadequate hygiene practices.

Children are disproportionately affected, with peak incidence between 5 to <15 years old. Studies show a significant proportion of cases in children under five years old, with notable morbidity and mortality. Limited data exist on the impact of typhoid fever on pregnant women, but some suggest potential maternal complications and adverse pregnancy outcomes.

The distribution of enteric fever in Sri Lanka is concentrated in specific geographic regions within the country, with notably high infection rates reported in districts such as Vavuniya, Jaffna, Nuwara Eliya, Colombo, and Kegalle. This pattern is closely linked to the consumption of contaminated water and food. In districts located in the dry zone, such as Jaffna and Vavuniya, water scarcity exacerbates the problem, while in the hill country, contamination of natural water sources, particularly springs, is a primary concern. Additionally, various dietary practices and inadequate sanitary facilities contribute to outbreaks in both regions. Children and the elderly, particularly those in lowincome groups, are particularly vulnerable to these intestinal infections and the highest disease incidence is observed among individuals aged 5-9 years, with two-thirds of all cases occurring in individuals aged 1-34 years.

Pathogen

Salmonella, a genus within the family Enterobacteriaceae, are rod-shaped, Gram-negative, facultative anaerobic bacteria. Most Salmonellae are motile due to peritrichous flagella, which bear the H antigen(s). Salmonella enterica subspecies enterica serovar Typhi, commonly known as S. Typhi, is a specific taxonomic designation within Salmonella. Alongside the H antigen(s), two polysaccharide surface antigens— the somatic O antigen and the capsular Vi (virulence) antigen—aid in further characterizing S. enterica. The Vi antigen is linked to resistance against complement-mediated bacterial lysis and activation of the alternate pathway of complement.

Salmonella enterica serovars Paratyphi A and Paratyphi B (and infrequently Paratyphi C) cause a disease known as paratyphoid fever, which clinically resembles typhoid fever, especially in certain regions of Asia. Together, Typhoid fever and Paratyphoid fever are referred to as enteric fever. While S. Typhi and S. Paratyphi C express the Vi antigen, it is absent in S. Paratyphi A and B.

Pathogenesis and Symptoms

After ingestion, S. Typhi enters a phase of silent primary bacteremia, reaching the reticuloendothelial system where it multiplies within macrophages. Following an average incubation period of 7–14 days (though it can range from 3 to 60 days), patients develop a spectrum of symptoms, with more severe cases marked by persistent high fever, abdominal discomfort, malaise,

Contents									
1. Epidemiology and Prevention of Typhoid Fever: Disease Dynamics and Vaccination	1								
2. Summary of selected notifiable diseases reported $(23^{rd} - 29^{th} \text{ March } 2024)$	3								
3. Surveillance of vaccine preventable diseases & AFP (23 rd – 29 th March 2024)	4								

WER Sri Lanka - Vol. 51 No. 14

and headache. Older children and adults may experience constipation or diarrhoea, while younger children more commonly suffer from diarrhoea. Individuals with certain forms of immunosuppression, achlorhydria, or those ingesting S. Typhi in food capable of neutralizing gastric acid, are more susceptible to lower infectious doses and are at higher risk of severe illness.

Complications arise in an estimated 10–15% of hospitalized patients, particularly among those whose illness persists for over 2 weeks. The most frequent life-threatening complications include intestinal haemorrhage, intestinal perforation, and encephalopathy leading to hemodynamic shock. Intestinal perforation rates in some outbreaks have exceeded 40%, with associated mortality rates ranging from 18% to 43%.

Chronic gallbladder carriage of S. Typhi can develop in approximately 2%–5% of cases, depending on factors such as the individual's age and the presence of pre-existing gallbladder mucosa disease. This chronic carrier state may also result from subclinical S. Typhi infection. Individuals in this state face an increased risk of developing hepatobiliary cancer. Chronic carriers serve as a source of ongoing infection, perpetuating the long-term prevalence of typhoid fever within communities by continuously shedding S. Typhi into the environment. Additionally, if carriers are involved in food handling, short-cycle transmission can occur through contaminated food.

Diagnosis

The vague symptoms of typhoid fever pose challenges for clinical diagnosis, often leading to confusion with other common febrile illnesses in regions where typhoid fever is prevalent. Relying solely on clinical diagnosis can skew surveillance data, inaccurately reflecting the true incidence of typhoid fever, and may result in inappropriate treatment. Typically, confirmation of the diagnosis relies on isolating S. Typhi through blood culture, but the sensitivity of a single blood culture is around 60% and can be influenced by the volume of blood obtained. This sensitivity is further diminished by the common practice of initiating antibiotic treatment before confirming the diagnosis. Blood culture is often not performed for the majority of cases in low and middle-income countries (LMICs), particularly in non-hospital settings. Additionally, some countries underutilize blood culture in infants and young children, leading to an underestimation of the typhoid fever burden in these age groups. Existing serological tests are limited by variable antibody responses to the pathogen and cross-reactivity of S. Typhi (and S. Paratyphi A) with other enteric bacteria.

Compiled by:

Dr. Rimaza Niyas Senior Registrar in Community Medicine Epidemiology Unit Ministry of Health

References

- Epidemiology Unit (2017). Combating Typhoid Fever. Weekly Epidemiological Review, Vol 44, No. 04
- Parry, C. M., Thompson, C., Vinh, H., Chinh, N. T., Phuong, L. T., Ho, V. A., ... & Baker, S. (2014). Risk factors for the development of severe typhoid fever in Vietnam. *BMC Infectious Diseases*, 14, 1-9.
- Voysey, M., & Pollard, A. J. (2018). Seroefficacy of Vi polysaccharide–tetanus toxoid typhoid conjugate vaccine (Typbar TCV). *Clinical Infectious Diseases*, 67(1), 18-24.
- World Health Organization. (2023). Typhoid: Key Facts. Retrieved from <u>https://www.who.int/news-room/</u> <u>fact-sheets/detail/typhoid</u> on 30.03.2024
- World Health Organization. (2019) Typhoid vaccines: WHO position paper, March 2018– Recommendations. *Vaccine*, *37*(2), 214-216.
- World Health Organization. (2018) Typhoid vaccine prequalified. Retrieved from <u>https://www.who.int/</u> <u>news/item/03-01-2018-typhoid-vaccine-prequalified</u> on 30.03.2024
- Yousafzai, M. T., Qamar, F. N., Shakoor, S., Saleem, K., Lohana, H., Karim, S., Hotwani, A., Qureshi, S., Masood, N., Rauf, M., Khanzada, J. A., Kazi, M., & Hasan, R. (2019). Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 68(Suppl 1), S16–S21. https://doi.org/10.1093/cid/ ciy877

Table 1: Selected notifiable diseases reported by Medical Officers of Health 23rd-29th Mar 2024 (13th Week)													-\																
Tap		_	_				_			-		_	-						_				_		_	-	_		.)
WRCD	°*	100	100	200	100	100	100	100	100	100	93	100	100	100	100	100	100	100	97	66 9	100	100	100	100	100	100	100	66	
8	*⊢	100	93	80	100	100	100	100	100	100	100	100	100	100	100	100	100	92	93	75	91	100	88	73	89	100	92	95	
Tuberculosis	в	542	303	184	175	37	76	120	38	28	56	7	17	7	7	30	64	18	135	53	69	26	62	26	63	86	38	2271	
Tuber	٨	44	27	17	7	9	ю	80	ю	ດ	2	0	0	0	0	0	З	0	5	2	4	9	9	~	0	ъ	З	165	
nania-	в	0	9	0	14	78	0	ო	150	29	0	0	~	5	4	~	9	00	147	8	244	136	00	66	63	12	0	989	
Leishmania-	۲	0	0	0	2	7	0	0	00	0	0	0	0	~	0	0	~	0	e	2	7	16	-	Q	5	0	0	58	
gitis	в	12	30	23	4	Q	с	24	12	38	9	0	2	9	0	19	19	ო	72	13	18	1	10	38	41	19	2	435	
Meningitis	٨	~	0	~	0	~	0	0	~	~	0	0	0	0	0	0	2	0	~	0	~	2	~	0	2J	0	~	18	
xodua	В	130	06	183	175	28	60	185	91	95	91	-	4	1	2	24	48	19	139	45	58	50	89	34	93	204	61	2010	
Chickenpox	A	23	10	,	с С	с	N	0		15	~	0	0	2	0	2J	e	0	13	4	7	с	4	0	4	14	~	152	
H. Rabiies	в	0	0	0	0	0	0	~	0	0	-	0	0	0	0	0	0	0	2	0	0	0	0	0	2	0	0	9	
H. R.	۲	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	~	0	0	-	
Viral Hep.	ш	ო	~	£	с С	4	ς,	4	0	~	e	0	0	4	0	9	e	0	N	0	9	~	7	7	o	£	~	80	
Vira	A	0	2	0	8	33	0	0	0	0	0	0	0	0	0	0	0	0	0	5 0	0	0	-	0	-	0	0	5	
Typhus F.	В	3		3		0	15	3 38	14	0 7	6 335	0 7	9	2	6	0	Ò	0	0 13	9	20	0	6	0 13	0 10	2	0	540	
	A	с С	0	0	~		~		~				0	~	~						~		2					22	
ptospirosis	В	132	190	3 206	5 79	0 39	3 69	251	6 229	3 102	0 12	10	0 16	3 50	46	0 21	3 102	0 81	7 223	115	6 180	6 109	200	381	496	183	34	3556	
Ľ	A	3 23	0 12	5 16	e e	8		11				-	0	2	, N					0 4	5	2	11	0 10	3 45	2 16	0	3 193	
F. Poisoning	В						1	17	28	4	15	~				12	7	~	339				16					486	
Ч.Ч.	A	0	0	0	0	0	0	~	20	0	0	0	0	4	0	0	0	0	0	0	0	0	~	0	0	0	0	26	
En. Fever	ш	2	0	9	0	-	~	-	~	0	S	-	-	0	0	0	0	-	0	0	0	0	0	-	0	0	0	26	
	۲	ς Γ	0	2	0	0	0	0	0	0	~	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	
Encephalitis	ш	e	4	0	0	0	e	7	~	ŝ	~	0	0	0	0	5	~	0		~	~	0	0	0	0	7	0	47	
Enc	۲	2	0	0	0	0	0	~	0	0	0	0	0	0	0	0	0	0	4	0	~	0	0	0	~	0	0	6	
Dysentery	В	2 2	Ω.	10	5	~	23	16	9	2	22	0	0	0	e	46	14	~	0	~	4	00	00	2	24	ŝ	00	237	
ð	A	0	0	10	0	4	6	0	-	0	1	0	0	4	0	0	9 2	0	-	4	0	-	4	0	-	0	4	2 12	
Dengue Fever	В	4015	1702	1105	1517	304	169	961	405	341	4750	258	169	124	169	982	129	389	1152	574	460	171	474	342	808	778	484	22732	
Deng	A	130	60	69	51	12	7	20	29	14	68	2	2	2	~	26	~	12	19	0	11	7	8	10	53	30	11	664	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	Nuwara Eliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunai	SRILANKA	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.lk). T=Timeliness refers to returns received on or before 29th Mar, 2024 Total number of reporting units 358 Number of reporting units data provided for the current week: 355 C**-Completeness • A = Cases reported during the current week. B = Cumulative cases for the year.

30th-05th Apr 2024

WER Sri Lanka - Vol. 51 No. 14

WER Sri Lanka - Vol. 51 No. 14

Table 2: Vaccine-Preventable Diseases & AFP

30th - 05th Apr 2024

23rd - 29th Mar 2024 (13th Week)

Disease	No. of Cases by Province										Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	W	С	S	Ν	Е	NW	NC	U	Sab	week in 2024	week in 2023	2024	2023	in 2024 & 2023	
AFP*	01	00	00	00	00	00	00	00	00	01	01	19	23	-17.4 %	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	01	00	00	00	00	00	01	01	00	03	10	72	61	18 %	
Measles	03	00	00	00	02	01	00	00	00	06	00	176	00	0 %	
Rubella	00	00	00	00	00	00	00	00	00	00	01	01	01	0 %	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Tetanus	00	00	00	00	00	00	01	00	00	01	00	01	01	0 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Japanese Enceph- alitis	00	00	00	00	00	00	00	00	00	00	00	01	01	0 %	
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, NT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

NA = Not Available

Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE

Dr. Samitha Ginige Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10